Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Accumulated Depreciation: 2017-2025

Historic Accumulated Depreciation for Crinetics Pharmaceuticals (CRNX) over the last 7 years, with Jun 2025 value amounting to $9.6 million.

  • Crinetics Pharmaceuticals' Accumulated Depreciation rose 53.84% to $9.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $9.6 million, marking a year-over-year increase of 53.84%. This contributed to the annual value of $7.7 million for FY2024, which is 52.57% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Accumulated Depreciation of $9.6 million as of Q2 2025, which was up 10.95% from $8.6 million recorded in Q1 2025.
  • Crinetics Pharmaceuticals' 5-year Accumulated Depreciation high stood at $9.6 million for Q2 2025, and its period low was $2.8 million during Q1 2021.
  • Its 3-year average for Accumulated Depreciation is $6.4 million, with a median of $5.9 million in 2024.
  • Data for Crinetics Pharmaceuticals' Accumulated Depreciation shows a peak YoY surged of 57.72% (in 2025) over the last 5 years.
  • Over the past 5 years, Crinetics Pharmaceuticals' Accumulated Depreciation (Quarterly) stood at $3.5 million in 2021, then grew by 17.36% to $4.1 million in 2022, then increased by 24.09% to $5.1 million in 2023, then surged by 52.57% to $7.7 million in 2024, then surged by 53.84% to $9.6 million in 2025.
  • Its last three reported values are $9.6 million in Q2 2025, $8.6 million for Q1 2025, and $7.7 million during Q4 2024.